{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,18]],"date-time":"2026-07-18T06:14:21Z","timestamp":1784355261915,"version":"3.55.0"},"reference-count":37,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2022,12]]},"abstract":"<jats:p>Sleep deprivation may induce anxiety. On the other hand, anxiety disorders elicit main changes in the quality of sleep. Moreover, orexin and citalopram play a role in the modulation of insomnia and mood diseases. Thus, we planned preclinical research to evaluate the effect of combinations of orexin agents and citalopram on anxiety behavior in rapid eye movement (REM) sleep-deprived mice. For drug intracerebroventricular (i.c.v.) infusion, the guide cannula was surgically implanted in the left lateral ventricle of mice. REM sleep deprivation was conducted via water tank apparatus for 24\u2009h. The anxiety behavior of mice was evaluated using the elevated plus maze (EPM). Our results revealed that REM sleep deprivation reduced the percentage of open arm time (%OAT) and the percentage of the open arm entries (%OAE) but not closed arm entries (locomotor activity) in the EPM test, presenting an anxiogenic response (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2009&lt;\u20090.05). We found a sub-threshold dose of SB-334867, orexin-1 receptor antagonist, and orexin-1 which did not alter anxiety reaction in the REM sleep-deprived mice (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2009&gt;\u20090.05). Intraperitoneal (i.p.) injections of citalopram (5 and 10 mg\/kg) increased both %OAT and %OAE (<jats:italic toggle=\"yes\">P<\/jats:italic>\u2009&lt;\u20090.001) representing an anxiolytic effect, but not locomotor activity in the REM sleep-deprived mice. Interestingly, co-treatment of citalopram (1, 5 and 10 mg\/kg; i.p.) and SB-334867 (0.1\u2009\u00b5g\/mouse; i.c.v.) potentiated the anxiolytic effect in the REM sleep-deprived mice. On the other hand, co-treatment of different dosages of citalopram along with a sub-threshold dose of orexin-1 did not alter %OAT, %OAE, and locomotor activity in the REM sleep-deprived mice. We found a synergistic anxiolytic effect of citalopram and SB-334867 in the REM sleep-deprived mice. These results suggested an interaction between citalopram and SB-334867 to prevent anxiogenic behavior in the REM sleep-deprived mice.<\/jats:p>","DOI":"10.1097\/fbp.0000000000000703","type":"journal-article","created":{"date-parts":[[2022,9,27]],"date-time":"2022-09-27T12:26:14Z","timestamp":1664281574000},"page":"559-566","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":2,"title":["The effects of citalopram, SB-334867 and orexin-1, alone or in various combinations, on the anxiogenic-like effects of REM sleep deprivation in male mice"],"prefix":"10.1097","volume":"33","author":[{"given":"Naghmeh","family":"Saadati","sequence":"first","affiliation":[{"name":"Department of Biology, Faculty of Biological Sciences, North Tehran Branch"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Bananej","sequence":"additional","affiliation":[{"name":"Department of Biology, Faculty of Biological Sciences, North Tehran Branch"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fatemeh","family":"Khakpai","sequence":"additional","affiliation":[{"name":"Department of Physiology, Faculty of Medicine, Tehran Medical Sciences, Islamic Azad University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohammad-Reza","family":"Zarrindast","sequence":"additional","affiliation":[{"name":"Department of Pharmacology, School of Medicine"},{"name":"Iranian National Center for Addiction Studies"},{"name":"Department of Neuroendocrinology, Endocrinology and Metabolism Clinical Sciences Institute, Tehran University of Medical Sciences, Tehran, Iran"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hengameh","family":"Alibeik","sequence":"additional","affiliation":[{"name":"Department of Biology, Faculty of Biological Sciences, North Tehran Branch"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"key":"R1-20250614","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1007\/s11011-020-00542-1","article-title":"Anxiety in rats with bile duct ligation is associated with activation of JNK3 mitogen-activated protein kinase in the hippocampus.","volume":"35","author":"Ahmadi","year":"2020","journal-title":"Metab Brain Dis"},{"key":"R2-20250614","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.biopha.2018.10.033","article-title":"Co-administration of the low dose of orexin and nitrergic antagonists induces an antidepressant-like effect in mice.","volume":"109","author":"Alijanpour","year":"2019","journal-title":"Biomed Pharmacother"},{"key":"R3-20250614","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2174\/1570159X11311030001","article-title":"Neurobiological consequences of sleep deprivation.","volume":"11","author":"Alkadhi","year":"2013","journal-title":"Curr Neuropharmacol"},{"key":"R5-20250614","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1016\/j.neuropharm.2017.07.008","article-title":"Inhibition of TrkB at the nucleus accumbens, using ANA-12, regulates basal and stress-induced orexin A expression within the mesolimbic system and affects anxiety, sociability and motivation.","volume":"125","author":"Azogu","year":"2017","journal-title":"Neuropharmacology"},{"key":"R6-20250614","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.pnpbp.2017.04.001","article-title":"Environmental enrichment reduces chronic psychosocial stress-induced anxiety and ethanol-related behaviors in mice.","volume":"77","author":"Bahi","year":"2017","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R7-20250614","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.euroneuro.2021.05.005","article-title":"Pharmacokinetic and pharmacodynamic interactions between daridorexant, a dual orexin receptor antagonist, and citalopram in healthy subjects.","volume":"51","author":"Berger","year":"2021","journal-title":"Eur Neuropsychopharmacol"},{"key":"R8-20250614","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1176\/appi.ps.201200226","article-title":"Frequent insufficient sleep and anxiety and depressive disorders among US community dwellers in 20 states, 2010.","volume":"64","author":"Chapman","year":"2013","journal-title":"Psychiatr Serv"},{"key":"R10-20250614","doi-asserted-by":"crossref","first-page":"27147","DOI":"10.1038\/srep27147","article-title":"Orexin 2 receptor antagonism is sufficient to promote NREM and REM sleep from mouse to man.","volume":"6","author":"Gotter","year":"2016","journal-title":"Sci Rep"},{"key":"R11-20250614","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1038\/npp.2008.141","article-title":"Two-week treatment with the selective serotonin reuptake inhibitor citalopram reduces contextual anxiety but not cued fear in healthy volunteers: a fear-potentiated startle study.","volume":"34","author":"Grillon","year":"2009","journal-title":"Neuropsychopharmacology"},{"key":"R12-20250614","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1038\/sj.npp.1301204","article-title":"A single dose of the selective serotonin reuptake inhibitor citalopram exacerbates anxiety in humans: a fear-potentiated startle study.","volume":"32","author":"Grillon","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"R14-20250614","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.neubiorev.2020.07.040","article-title":"Dysregulation of the orexinergic system: a potential neuropeptide target in depression.","volume":"118","author":"Khairuddin","year":"2020","journal-title":"Neurosci Biobehav Rev"},{"key":"R15-20250614","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.bbr.2016.12.007","article-title":"Increased anxiety but normal fear and safety learning in orexin-deficient mice.","volume":"320","author":"Khalil","year":"2017","journal-title":"Behav Brain Res"},{"key":"R16-20250614","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00019442-200501000-00011","article-title":"Generalized anxiety disorder in late life: lifetime course and comorbidity with major depressive disorder.","volume":"13","author":"Lenze","year":"2005","journal-title":"Am J Geriatr Psychiatry"},{"key":"R17-20250614","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1159\/000028269","article-title":"Acute and chronic citalopram treatment differently modulates rat exploratory behavior in the exploration box test: no evidence for increased anxiety or changes in the [3H]raclopride binding.","volume":"58","author":"Matto","year":"1999","journal-title":"Pharmacology"},{"key":"R18-20250614","doi-asserted-by":"crossref","first-page":"830","DOI":"10.3389\/fendo.2019.00830","article-title":"Orexins\/hypocretins: key regulators of energy homeostasis.","volume":"10","author":"Milbank","year":"2019","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R20-20250614","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pnpbp.2018.07.013","article-title":"Differential effects of citalopram on sleep-deprivation-induced depressive-like behavior and memory impairments in mice.","volume":"88","author":"Misrani","year":"2019","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"R21-20250614","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.brainresbull.2019.11.007","article-title":"Citalopram prevents sleep-deprivation-induced reduction in CaMKII-CREB-BDNF signaling in mouse prefrontal cortex.","volume":"155","author":"Misrani","year":"2020","journal-title":"Brain Res Bull"},{"key":"R22-20250614","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1017\/S1461145709990630","article-title":"Differential effects of acute and repeated citalopram in mouse models of anxiety and depression.","volume":"13","author":"Mombereau","year":"2010","journal-title":"Int J Neuropsychopharmacol"},{"key":"R23-20250614","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/j.neuroscience.2016.10.007","article-title":"Additive effect of harmane and muscimol for memory consolidation impairment in inhibitory avoidance task.","volume":"339","author":"Nasehi","year":"2016","journal-title":"Neuroscience"},{"key":"R24-20250614","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.bbr.2018.06.002","article-title":"The role of omega-3 on modulation of cognitive deficiency induced by REM sleep deprivation in rats.","volume":"351","author":"Nasehi","year":"2018","journal-title":"Behav Brain Res"},{"key":"R25-20250614","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.nlm.2017.03.022","article-title":"Synergistic effect between D-AP5 and muscimol in the nucleus accumbens shell on memory consolidation deficit in adult male Wistar rats: an isobologram analysis.","volume":"141","author":"Nasehi","year":"2017","journal-title":"Neurobiol Learn Mem"},{"key":"R26-20250614","doi-asserted-by":"crossref","first-page":"146701","DOI":"10.1016\/j.brainres.2020.146701","article-title":"Synergistic effect between citalopram and citicoline on anxiolytic effect in non-sensitized and morphine-sensitized mice: an isobologram analysis.","volume":"1734","author":"Nejati","year":"2020","journal-title":"Brain Res"},{"key":"R27-20250614","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.jpsychires.2015.12.005","article-title":"Sedation mediates part of Citalopram\u2019s effect on agitation in Alzheimer\u2019s disease.","volume":"74","author":"Newell","year":"2016","journal-title":"J Psychiatr Res"},{"key":"R28-20250614","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s40263-013-0064-z","article-title":"Role of orexin in the pathophysiology of depression: potential for pharmacological intervention.","volume":"27","author":"Nollet","year":"2013","journal-title":"CNS Drugs"},{"key":"R30-20250614","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/0091-3057(86)90552-6","article-title":"Anxiolytic and anxiogenic drug effects on exploratory activity in an elevated plus-maze: a novel test of anxiety in the rat.","volume":"24","author":"Pellow","year":"1986","journal-title":"Pharmacol Biochem Behav"},{"key":"R31-20250614","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1590\/S1679-45082012000400022","article-title":"Relationship between sleep deprivation and anxiety: experimental research perspective.","volume":"10","author":"Pires","year":"2012","journal-title":"Einstein (S\u00e3o Paulo)"},{"key":"R32-20250614","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/S0893-133X(99)00092-5","article-title":"Serotonin reuptake inhibition by citalopram in rat strains differing for their emotionality.","volume":"22","author":"Pollier","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"R33-20250614","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1093\/schbul\/sbm087","article-title":"The Orexin-1 antagonist SB-334867 blocks antipsychotic treatment\u2013emergent catalepsy: implications for the treatment of extrapyramidal symptoms.","volume":"33","author":"Rasmussen","year":"2006","journal-title":"Schizophr Bull"},{"key":"R34-20250614","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1080\/15402002.2011.533991","article-title":"Restricted sleep among adolescents: prevalence, incidence, persistence, and associated factors.","volume":"9","author":"Roberts","year":"2011","journal-title":"Behav Sleep Med"},{"key":"R35-20250614","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.bandc.2005.10.001","article-title":"Effects of sleep deprivation on Color-Word, Emotional, and Specific Stroop interference and on self-reported anxiety.","volume":"60","author":"Sagaspe","year":"2006","journal-title":"Brain Cogn"},{"key":"R36-20250614","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/2008-2231-21-4","article-title":"Comparing the effects of fluoxetine and imipramine on total cholesterol, triglyceride, and weight in patients with major depression.","volume":"21","author":"Shahsavand Ananloo","year":"2013","journal-title":"Daru"},{"key":"R37-20250614","doi-asserted-by":"crossref","first-page":"249","DOI":"10.31887\/DCNS.2003.5.3\/lstaner","article-title":"Sleep and anxiety disorders.","volume":"5","author":"Staner","year":"2003","journal-title":"Dialogues Clin Neurosci"},{"key":"R38-20250614","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.neuropharm.2018.09.016","article-title":"Orexin 2 receptor stimulation enhances resilience, while orexin 2 inhibition promotes susceptibility, to social stress, anxiety and depression.","volume":"143","author":"Staton","year":"2018","journal-title":"Neuropharmacology"},{"key":"R39-20250614","doi-asserted-by":"crossref","first-page":"146085","DOI":"10.1016\/j.brainres.2018.12.036","article-title":"Orexin\/hypocretin receptor modulation of anxiolytic and antidepressive responses during social stress and decision-making: potential for therapy.","volume":"1731","author":"Summers","year":"2020","journal-title":"Brain Res"},{"key":"R40-20250614","doi-asserted-by":"crossref","first-page":"146085","DOI":"10.1016\/j.brainres.2018.12.036","article-title":"Orexin\/hypocretin receptor modulation of anxiolytic and antidepressive responses during social stress and decision-making: potential for therapy.","volume":"1731","author":"Summers","year":"2020","journal-title":"Brain Res"},{"key":"R41-20250614","doi-asserted-by":"crossref","first-page":"100059","DOI":"10.1016\/j.medidd.2020.100059","article-title":"Counterbalanced microcircuits for Orx1 and Orx2 regulation of stress reactivity.","volume":"8","author":"Yaeger","year":"2020","journal-title":"Med Drug Discov"},{"key":"R42-20250614","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.biopsych.2021.12.019","article-title":"Orexin 1 receptor antagonism in the basolateral amygdala shifts the balance from pro- to antistress signaling and behavior.","volume":"91","author":"Yaeger","year":"2022","journal-title":"Biol Psychiatry"}],"container-title":["Behavioural Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000703","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,14]],"date-time":"2025-06-14T22:01:37Z","timestamp":1749938497000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/FBP.0000000000000703"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":37,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/fbp.0000000000000703","relation":{},"ISSN":["0955-8810"],"issn-type":[{"value":"0955-8810","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10,6]]}}}